OR WAIT null SECS
Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
This articles is part of the State of Urology 2014
Dr. ThrasherResearch in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer (mCRPC), including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
“At this year’s annual meeting, we will hear more about optimal sequencing and use of the new drugs recently approved for mCRPC and get a glimpse at new agents being tested,” said J. Brantley Thrasher, MD, professor and chair of urology at the University of Kansas Medical Center, Kansas City.
Early-stage trials will examine the anti-cancer activity of VT-464, a small molecule CYP17A1 inhibitor, and Prostate Specific Membrane Antigen Antibody Drug Conjugate, a human antibody to PSMA.
Specifically, here are the can't-miss abstracts from this year's AUA annual meeting, as selected by Dr. Thrasher:
PD27-06: Simvastatin and Metformin: A Deadly Combination for Metastatic Castration-Resistant Prostate Cancer
PD27-11: A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Methylphenidate for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy
Patrick O. Richard
PD27-12: Biochemical efficacy of Enzalutamide in post-chemo mCRPC patients previously treated with Abiraterone
M. Andreas Røder
MP70-02: Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED
MP70-05: Anti-cancer activity of the selective CYP17A1 inhibitor, VT-464, in pre-clinical models of castrate-resistant prostate cancer
MP70-10: Further Characterization of the Effects of Prior or No Prior Docetaxel Therapy on CRPC Patients With Bone Metastases Receiving Ra-223 in the Phase 3 ALSYMPCA Trial
MP70-13: Impact of Screening and treatment pattern on Racial and Ethnic Differences in Outcomes among Advanced Stage Prostate Cancer Patients
MP70-18: Mortality in men with advanced prostate cancer may be reduced with radical treatment compared to androgen deprivation alone
MP70-20: A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Subscribe to Urology Times to get monthly news from the leading news source for urologists.